Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia: an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02
Objective - To evaluate the safety and tolerability of higher doses of sildenafil in neonates with hypoxic-ischemic encephalopathy (HIE) and brain injury. - Study design - A phase 1b open-label dose-finding clinical trial in neonates with moderate-severe HIE and confirmed brain injury on a day-2 mag...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 2025
|
| In: |
The journal of pediatrics
Year: 2025, Volume: 285, Pages: 1-10 |
| ISSN: | 1097-6833 |
| DOI: | 10.1016/j.jpeds.2025.114701 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jpeds.2025.114701 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0022347625002422 
|
| Author Notes: | Pia Wintermark, MD, Anie Lapointe, MD, MSc, Gabriel Altit, MD, MSc, Robin Steinhorn, MD, Emmanouil Rampakakis, PhD, Andreas D. Meid, Dr. Sc. Hum, Jürgen Burhenne, PhD, Gzona Bajraktari-Sylejmani, PhD, May Khairy, D, Marie-Therese Adamo, BPharm, MSc, Guillaume Gilbert, PhD, Daniela Toffoli, MD, Samara Zavalkoff, MD, Thuy Mai Luu, MD, Elizabeth Hailu, MD, MSc, FAAP, and Walter E. Haefeli, MD |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1945025352 | ||
| 003 | DE-627 | ||
| 005 | 20251208122048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251208s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpeds.2025.114701 |2 doi | |
| 035 | |a (DE-627)1945025352 | ||
| 035 | |a (DE-599)KXP1945025352 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wintermark, Pia |e VerfasserIn |0 (DE-588)120998234X |0 (DE-627)169805873X |4 aut | |
| 245 | 1 | 0 | |a Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia |b an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02 |c Pia Wintermark, MD, Anie Lapointe, MD, MSc, Gabriel Altit, MD, MSc, Robin Steinhorn, MD, Emmanouil Rampakakis, PhD, Andreas D. Meid, Dr. Sc. Hum, Jürgen Burhenne, PhD, Gzona Bajraktari-Sylejmani, PhD, May Khairy, D, Marie-Therese Adamo, BPharm, MSc, Guillaume Gilbert, PhD, Daniela Toffoli, MD, Samara Zavalkoff, MD, Thuy Mai Luu, MD, Elizabeth Hailu, MD, MSc, FAAP, and Walter E. Haefeli, MD |
| 264 | 1 | |c October 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 23. Juni 2025, Artikelversion: 14. Juli 2025 | ||
| 500 | |a Gesehen am 08.12.2025 | ||
| 520 | |a Objective - To evaluate the safety and tolerability of higher doses of sildenafil in neonates with hypoxic-ischemic encephalopathy (HIE) and brain injury. - Study design - A phase 1b open-label dose-finding clinical trial in neonates with moderate-severe HIE and confirmed brain injury on a day-2 magnetic resonance imaging during therapeutic hypothermia (TH). Enteral sildenafil was administered every 12 hours (q12 h) for 7 days. All participants received an initial dose 2.0 mg/kg, and a second dose of 2.5 mg/kg. Starting from the third dose, group 1 received 2.5 mg/kg q12 h and group 2 received 3.0 mg/kg q12 h. Primary outcome was incidence of dose-limiting toxicities. Secondary outcomes explored day-30 neuroimaging and 18-month neurodevelopment. - Results - Among the 30 neonates born between October 2019 and December 2021, 20 displayed day-2 brain injury and 13 received sildenafil (8 in group 1; 5 in group 2). In group 1, 25% (2/8) experienced transient hypotension after the first dose, linked to antiseizure medications. No significant hypotension occurred in group 2 when sildenafil was administered separately. At the 3.0 mg/kg/dose, steady-state sildenafil concentrations persisted beyond TH. Death or significant 18-month neurodevelopmental impairment occurred in 50% (4/8) of group 1 and 60% (3/5) of group 2. Among the survivors, partial recovery of brain injury was seen in 80% (4/5) of group 1 and 75% (3/4) of group 2; cerebral palsy developed in 0% (0/5) and 50% (2/4), respectively. - Conclusions - Enteral sildenafil up to 3.0 mg/kg q12 h was safe and well tolerated in a small single-center cohort of neonates with HIE treated with TH. Phase 2 trials are needed to assess multicenter feasibility and efficacy. - Trial registration - ClinicalTrials.gov NCT04169191. | ||
| 650 | 4 | |a birth asphyxia | |
| 650 | 4 | |a brain | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a hypothermia, magnetic resonance imaging | |
| 650 | 4 | |a hypoxic-ischemic encephalopathy | |
| 650 | 4 | |a neonatal encephalopathy | |
| 650 | 4 | |a neonate | |
| 650 | 4 | |a neuroprevention, neurorestoration | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a sildenafil | |
| 700 | 1 | |a Lapointe, Anie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Altit, Gabriel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steinhorn, Robin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rampakakis, Emmanouil |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meid, Andreas |d 1981- |e VerfasserIn |0 (DE-588)1076301991 |0 (DE-627)834660377 |0 (DE-576)445184582 |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Bajraktari-Sylejmani, Gzona |e VerfasserIn |0 (DE-588)1152395823 |0 (DE-627)1013994760 |0 (DE-576)499867106 |4 aut | |
| 700 | 1 | |a Khairy, May |e VerfasserIn |4 aut | |
| 700 | 1 | |a Adamo, Marie-Therese |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gilbert, Guillaume |e VerfasserIn |4 aut | |
| 700 | 1 | |a Toffoli, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zavalkoff, Samara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Luu, Thuy Mai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hailu, Elizabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of pediatrics |d St. Louis, Mo. : Mosby, 1932 |g 285(2025) vom: Okt., Artikel-ID 114701, Seite 1-10 |h Online-Ressource |w (DE-627)315966548 |w (DE-600)2005245-5 |w (DE-576)090887085 |x 1097-6833 |7 nnas |a Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02 |
| 773 | 1 | 8 | |g volume:285 |g year:2025 |g month:10 |g elocationid:114701 |g pages:1-10 |g extent:10 |a Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jpeds.2025.114701 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0022347625002422 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20251208 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 16 |y j | ||
| 998 | |g 1152395823 |a Bajraktari-Sylejmani, Gzona |m 1152395823:Bajraktari-Sylejmani, Gzona |d 910000 |d 910100 |e 910000PB1152395823 |e 910100PB1152395823 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1076301991 |a Meid, Andreas |m 1076301991:Meid, Andreas |d 50000 |e 50000PM1076301991 |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1945025352 |e 4824353505 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Wintermark","display":"Wintermark, Pia","given":"Pia","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Anie","display":"Lapointe, Anie","family":"Lapointe"},{"given":"Gabriel","roleDisplay":"VerfasserIn","role":"aut","display":"Altit, Gabriel","family":"Altit"},{"family":"Steinhorn","display":"Steinhorn, Robin","roleDisplay":"VerfasserIn","role":"aut","given":"Robin"},{"family":"Rampakakis","given":"Emmanouil","role":"aut","roleDisplay":"VerfasserIn","display":"Rampakakis, Emmanouil"},{"family":"Meid","role":"aut","roleDisplay":"VerfasserIn","given":"Andreas","display":"Meid, Andreas"},{"given":"Jürgen","roleDisplay":"VerfasserIn","role":"aut","display":"Burhenne, Jürgen","family":"Burhenne"},{"family":"Bajraktari-Sylejmani","given":"Gzona","roleDisplay":"VerfasserIn","role":"aut","display":"Bajraktari-Sylejmani, Gzona"},{"given":"May","roleDisplay":"VerfasserIn","role":"aut","display":"Khairy, May","family":"Khairy"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Marie-Therese","display":"Adamo, Marie-Therese","family":"Adamo"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Guillaume","display":"Gilbert, Guillaume","family":"Gilbert"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Daniela","display":"Toffoli, Daniela","family":"Toffoli"},{"display":"Zavalkoff, Samara","role":"aut","roleDisplay":"VerfasserIn","given":"Samara","family":"Zavalkoff"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Thuy Mai","display":"Luu, Thuy Mai","family":"Luu"},{"family":"Hailu","display":"Hailu, Elizabeth","role":"aut","roleDisplay":"VerfasserIn","given":"Elizabeth"},{"family":"Haefeli","given":"Walter E.","roleDisplay":"VerfasserIn","role":"aut","display":"Haefeli, Walter E."}],"relHost":[{"title":[{"title_sort":"journal of pediatrics","title":"The journal of pediatrics"}],"disp":"Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02The journal of pediatrics","language":["eng"],"origin":[{"dateIssuedDisp":"1932-","publisher":"Mosby ; Elsevier","dateIssuedKey":"1932","publisherPlace":"St. Louis, Mo. ; Frankfurt a. M. [u.a.]"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1097-6833"],"zdb":["2005245-5"],"eki":["315966548"]},"note":["Gesehen am 15.01.20"],"part":{"volume":"285","year":"2025","extent":"10","pages":"1-10","text":"285(2025) vom: Okt., Artikel-ID 114701, Seite 1-10"},"recId":"315966548","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1932 -"]}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"name":{"displayForm":["Pia Wintermark, MD, Anie Lapointe, MD, MSc, Gabriel Altit, MD, MSc, Robin Steinhorn, MD, Emmanouil Rampakakis, PhD, Andreas D. Meid, Dr. Sc. Hum, Jürgen Burhenne, PhD, Gzona Bajraktari-Sylejmani, PhD, May Khairy, D, Marie-Therese Adamo, BPharm, MSc, Guillaume Gilbert, PhD, Daniela Toffoli, MD, Samara Zavalkoff, MD, Thuy Mai Luu, MD, Elizabeth Hailu, MD, MSc, FAAP, and Walter E. Haefeli, MD"]},"id":{"eki":["1945025352"],"doi":["10.1016/j.jpeds.2025.114701"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"October 2025"}],"title":[{"subtitle":"an open-label dose-finding phase 1b clinical trial-sildenafil administration to treat neonatal encephalopathy-study 02","title":"Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia","title_sort":"Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1945025352","note":["Online verfügbar: 23. Juni 2025, Artikelversion: 14. Juli 2025","Gesehen am 08.12.2025"]} | ||
| SRT | |a WINTERMARKTESTINGHIG2025 | ||